Sinopharm Reports Unchanged Share Capital and Sufficient Public Float for June 2026

Bulletin Express07-06

Sinopharm Group Co. Ltd. disclosed its Monthly Return for Equity Issuer for the period ended 30 June 2026, confirming a stable capital structure and full compliance with Hong Kong Stock Exchange public-float requirements.

Share Capital Structure • Authorised / Registered Capital: 3.12 billion shares with a par value of RMB 1 each, translating into authorised share capital of RMB 3.12 billion. • Issued Shares: 3.12 billion, split between 1.34 billion H shares and 1.78 billion domestic shares. • Treasury Shares: Zero. • Monthly Movement: No increase or decrease was recorded in either authorised or issued share capital during June 2026.

Public-Float Compliance • The company confirmed adherence to Main Board Rule 13.32B, maintaining at least 25 % public float for its H shares. • No share repurchases, cancellations, or treasury transactions occurred that would affect float levels.

Equity Instruments and Other Arrangements • No share options, warrants, convertible securities or other agreements to issue additional shares were outstanding or executed in the month.

Administrative Details • The return was submitted to Hong Kong Exchanges and Clearing Limited on 06 July 2026 by Company Secretary Wu Yijian.

The absence of share-capital changes and the confirmed public-float sufficiency underscore Sinopharm’s stable equity position as at end-June 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168021182?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-06 17:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168021182","market":"us","top_or_hot":-1,"title":"Sinopharm Reports Unchanged Share Capital and Sufficient Public Float for June 2026","media":"Bulletin Express","content":"<p>Sinopharm Group Co. Ltd. disclosed its Monthly Return for Equity Issuer for the period ended 30 June 2026, confirming a stable capital structure and full compliance with Hong Kong Stock Exchange public-float requirements.</p>\n<p>Share Capital Structure  \n• Authorised / Registered Capital: 3.12 billion shares with a par value of RMB 1 each, translating into authorised share capital of RMB 3.12 billion.  \n• Issued Shares: 3.12 billion, split between 1.34 billion H shares and 1.78 billion domestic shares.  \n• Treasury Shares: Zero.  \n• Monthly Movement: No increase or decrease was recorded in either authorised or issued share capital during June 2026.</p>\n<p>Public-Float Compliance  \n• The company confirmed adherence to Main Board Rule 13.32B, maintaining at least 25 % public float for its H shares.  \n• No share repurchases, cancellations, or treasury transactions occurred that would affect float levels.</p>\n<p>Equity Instruments and Other Arrangements  \n• No share options, warrants, convertible securities or other agreements to issue additional shares were outstanding or executed in the month.</p>\n<p>Administrative Details  \n• The return was submitted to Hong Kong Exchanges and Clearing Limited on 06 July 2026 by Company Secretary Wu Yijian.</p>\n<p>The absence of share-capital changes and the confirmed public-float sufficiency underscore Sinopharm’s stable equity position as at end-June 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sinopharm Reports Unchanged Share Capital and Sufficient Public Float for June 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinopharm Reports Unchanged Share Capital and Sufficient Public Float for June 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-06 17:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sinopharm Group Co. Ltd. disclosed its Monthly Return for Equity Issuer for the period ended 30 June 2026, confirming a stable capital structure and full compliance with Hong Kong Stock Exchange public-float requirements.</p>\n<p>Share Capital Structure  \n• Authorised / Registered Capital: 3.12 billion shares with a par value of RMB 1 each, translating into authorised share capital of RMB 3.12 billion.  \n• Issued Shares: 3.12 billion, split between 1.34 billion H shares and 1.78 billion domestic shares.  \n• Treasury Shares: Zero.  \n• Monthly Movement: No increase or decrease was recorded in either authorised or issued share capital during June 2026.</p>\n<p>Public-Float Compliance  \n• The company confirmed adherence to Main Board Rule 13.32B, maintaining at least 25 % public float for its H shares.  \n• No share repurchases, cancellations, or treasury transactions occurred that would affect float levels.</p>\n<p>Equity Instruments and Other Arrangements  \n• No share options, warrants, convertible securities or other agreements to issue additional shares were outstanding or executed in the month.</p>\n<p>Administrative Details  \n• The return was submitted to Hong Kong Exchanges and Clearing Limited on 06 July 2026 by Company Secretary Wu Yijian.</p>\n<p>The absence of share-capital changes and the confirmed public-float sufficiency underscore Sinopharm’s stable equity position as at end-June 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01099","symbol_name":"国药控股","start_time":0,"source_url":"","article_id":"1168021182","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168021182","pubTimestamp":1783328785,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Sinopharm Group Co. Ltd. disclosed its Monthly Return for Equity Issuer for the period ended 30 June 2026, confirming a stable capital structure and full compliance with Hong Kong Stock Exchange...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01099":"国药控股"},"translate_title":"国药控股报告2026年6月股本不变且公众持股量充足","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01099":1},"content_text":"Sinopharm Group Co. Ltd. disclosed its Monthly Return for Equity Issuer for the period ended 30 June 2026, confirming a stable capital structure and full compliance with Hong Kong Stock Exchange public-float requirements.\nShare Capital Structure  \n• Authorised / Registered Capital: 3.12 billion shares with a par value of RMB 1 each, translating into authorised share capital of RMB 3.12 billion.  \n• Issued Shares: 3.12 billion, split between 1.34 billion H shares and 1.78 billion domestic shares.  \n• Treasury Shares: Zero.  \n• Monthly Movement: No increase or decrease was recorded in either authorised or issued share capital during June 2026.\nPublic-Float Compliance  \n• The company confirmed adherence to Main Board Rule 13.32B, maintaining at least 25 % public float for its H shares.  \n• No share repurchases, cancellations, or treasury transactions occurred that would affect float levels.\nEquity Instruments and Other Arrangements  \n• No share options, warrants, convertible securities or other agreements to issue additional shares were outstanding or executed in the month.\nAdministrative Details  \n• The return was submitted to Hong Kong Exchanges and Clearing Limited on 06 July 2026 by Company Secretary Wu Yijian.\nThe absence of share-capital changes and the confirmed public-float sufficiency underscore Sinopharm’s stable equity position as at end-June 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168021182","isCrawlerRequest":true}